DEVELOPMENT OF A NEW IMMUNOMODULATING DRUG TIMOFER
Results of the development of an immunomodulating drug timofer based on coordination compounds isoleucyl-tryptophan dipeptide with iron (II), including the study of coordinate isoleucyl-tryptophan dipeptide with iron (II), the study of the immunostimulatory activity of the coordination compounds, th...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Volgograd State Medical University, Pyatigorsk Medical and Pharmaceutical Institute
2015-09-01
|
| Series: | Фармация и фармакология (Пятигорск) |
| Subjects: | |
| Online Access: | https://www.pharmpharm.ru/jour/article/view/28 |
| _version_ | 1797874772938326016 |
|---|---|
| author | B. M. Kholnazarov G. M. Bobiev N. D. Bunyatyan |
| author_facet | B. M. Kholnazarov G. M. Bobiev N. D. Bunyatyan |
| author_sort | B. M. Kholnazarov |
| collection | DOAJ |
| description | Results of the development of an immunomodulating drug timofer based on coordination compounds isoleucyl-tryptophan dipeptide with iron (II), including the study of coordinate isoleucyl-tryptophan dipeptide with iron (II), the study of the immunostimulatory activity of the coordination compounds, the results of the preclinical and clinical studies of timotsin are presented. Method of pH titration showed that the interaction of zinc and dipeptide isoleucyltryptophan formed in solution following complex forms: [Fe (HL±)]2+ (β = 1,00×1034), [Fe(HL±)2]2+ (β = 6,25×1011), [Fe (HL±)OH]+ (β = 4,01×1026), [Fe (L)]+ (β = 8,10×1018), [Fe (L)2]+ (β = 7,50×1028), [Fe (L)OH]+ (β = 1,03×1029). It was shown that the immunostimulatory activity of the coordination compounds is 2 times higher than that starting dipeptide. The substance sample and standard formulation of timofer were developed and standardized. The developed immunomodulatory drug timofer showed a high therapeutic efficacy in the treatment of iron deficiency anemia patients with inflammatory processes and traumatic injuries of the maxillofacial region, with chronic inflammatory diseases of the the genitals (CMV, HSV, chlamydia, chronic endometritis, chronic salpingoopharitis, ureaplasmosis) with chronic bronchitis, chronic obstructive bronchitis, bronchial asthma, pneumonia, chronic glomerulonephritis, and chronic renal failure complicated by anemia Bright, withrheumatic diseases, gynecological patients with anemia of moderate and severe degrees of severity, at surgical treatment of patients with suppurative lung disease, heart disease and chronic pericarditis operated with cardiopulmonary bypass. Timofer is registered in Tajikistan (registration number of medical drug №002866). |
| first_indexed | 2024-04-10T01:37:15Z |
| format | Article |
| id | doaj.art-b09b7d333da046b299a19a83e3d22553 |
| institution | Directory Open Access Journal |
| issn | 2307-9266 2413-2241 |
| language | Russian |
| last_indexed | 2024-04-10T01:37:15Z |
| publishDate | 2015-09-01 |
| publisher | Volgograd State Medical University, Pyatigorsk Medical and Pharmaceutical Institute |
| record_format | Article |
| series | Фармация и фармакология (Пятигорск) |
| spelling | doaj.art-b09b7d333da046b299a19a83e3d225532023-03-13T09:18:09ZrusVolgograd State Medical University, Pyatigorsk Medical and Pharmaceutical InstituteФармация и фармакология (Пятигорск)2307-92662413-22412015-09-0122(3)889710.19163/2307-9266-2014-2-2(3)-88-9728DEVELOPMENT OF A NEW IMMUNOMODULATING DRUG TIMOFERB. M. Kholnazarov0G. M. Bobiev1N. D. Bunyatyan2Таджикский национальный университет, г.Душанбе, ТаджикистанТаджикский государственный педагогический университет им. С.Айни, г.Душанбе, ТаджикистанФГБУ «Научный центр экспертизы средств медицинского применения» Минздрава России, г. МоскваResults of the development of an immunomodulating drug timofer based on coordination compounds isoleucyl-tryptophan dipeptide with iron (II), including the study of coordinate isoleucyl-tryptophan dipeptide with iron (II), the study of the immunostimulatory activity of the coordination compounds, the results of the preclinical and clinical studies of timotsin are presented. Method of pH titration showed that the interaction of zinc and dipeptide isoleucyltryptophan formed in solution following complex forms: [Fe (HL±)]2+ (β = 1,00×1034), [Fe(HL±)2]2+ (β = 6,25×1011), [Fe (HL±)OH]+ (β = 4,01×1026), [Fe (L)]+ (β = 8,10×1018), [Fe (L)2]+ (β = 7,50×1028), [Fe (L)OH]+ (β = 1,03×1029). It was shown that the immunostimulatory activity of the coordination compounds is 2 times higher than that starting dipeptide. The substance sample and standard formulation of timofer were developed and standardized. The developed immunomodulatory drug timofer showed a high therapeutic efficacy in the treatment of iron deficiency anemia patients with inflammatory processes and traumatic injuries of the maxillofacial region, with chronic inflammatory diseases of the the genitals (CMV, HSV, chlamydia, chronic endometritis, chronic salpingoopharitis, ureaplasmosis) with chronic bronchitis, chronic obstructive bronchitis, bronchial asthma, pneumonia, chronic glomerulonephritis, and chronic renal failure complicated by anemia Bright, withrheumatic diseases, gynecological patients with anemia of moderate and severe degrees of severity, at surgical treatment of patients with suppurative lung disease, heart disease and chronic pericarditis operated with cardiopulmonary bypass. Timofer is registered in Tajikistan (registration number of medical drug №002866).https://www.pharmpharm.ru/jour/article/view/28иммуномодулирующий препараттимоферкоординационные соединенияизолейцил-триптофанжелезо |
| spellingShingle | B. M. Kholnazarov G. M. Bobiev N. D. Bunyatyan DEVELOPMENT OF A NEW IMMUNOMODULATING DRUG TIMOFER Фармация и фармакология (Пятигорск) иммуномодулирующий препарат тимофер координационные соединения изолейцил-триптофан железо |
| title | DEVELOPMENT OF A NEW IMMUNOMODULATING DRUG TIMOFER |
| title_full | DEVELOPMENT OF A NEW IMMUNOMODULATING DRUG TIMOFER |
| title_fullStr | DEVELOPMENT OF A NEW IMMUNOMODULATING DRUG TIMOFER |
| title_full_unstemmed | DEVELOPMENT OF A NEW IMMUNOMODULATING DRUG TIMOFER |
| title_short | DEVELOPMENT OF A NEW IMMUNOMODULATING DRUG TIMOFER |
| title_sort | development of a new immunomodulating drug timofer |
| topic | иммуномодулирующий препарат тимофер координационные соединения изолейцил-триптофан железо |
| url | https://www.pharmpharm.ru/jour/article/view/28 |
| work_keys_str_mv | AT bmkholnazarov developmentofanewimmunomodulatingdrugtimofer AT gmbobiev developmentofanewimmunomodulatingdrugtimofer AT ndbunyatyan developmentofanewimmunomodulatingdrugtimofer |